Loading ...
Sorry, an error occurred while loading the content.

Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months

Expand Messages
  • claudine intexas
    Hepatol Res 2003 Mar;25(3):226-233 Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Ishii K, Takamura N,
    Message 1 of 1 , Apr 23, 2003
    • 0 Attachment
      Hepatol Res 2003 Mar;25(3):226-233

      Long-term follow-up of chronic hepatitis C patients treated with oral
      lactoferrin for 12 months.

      Ishii K, Takamura N, Shinohara M, Wakui N, Shin H, Sumino Y, Ohmoto
      Y, Teraguchi S, Yamauchi K.

      Second Department of Internal Medicine, Toho University School of
      Medicine, 6-11-1, Omori-nishi, Ota-ku, 143, Tokyo, Japan

      BACKGROUND/AIMS: Bovine lactoferrin (bLF) has been shown to prevent
      the infection of cultured hepatocytes by hepatitis C virus (HCV). The
      present study attempted to clarify the effects of long-term
      administration of bLF on serum parameters, including immunomodulatory
      cytokines, in patients with chronic hepatitis C (CHC). METHODS:
      Sixty-three CHC patients were randomly assigned into 2 groups. At an
      oral dose of 600 mg/day, bLF was administered for 12 months to 36
      patients (bLF group), while no bLF was given to the remaining 27
      patients (control group. Serum levels of alanine aminotransferase,
      HCV-RNA, IL-10, and IL-18 were evaluated, as well as CD4-positive T
      cell subsets in the peripheral blood. RESULTS: The serum IL-18 level
      was increased by bLF administration, but not in the control group.
      After 3 months of bLF treatment, it was significantly higher than
      before bLF administration, but it decreased gradually thereafter. The
      percentage of interferon (IFN)-gamma+ and IL-4- (Th1) cells in the
      peripheral blood increased along with the serum IL-18 level, although
      the change was not statistically significant. The other parameters
      did not change significantly during the study period in both groups.
      CONCLUSIONS: These results suggest that oral administration of bLF to
      CHC patients for up to 3 months can produce a Th1-cytokine dominant
      environment in the peripheral blood that favors the eradication of
      HCV by IFN therapy.

      PMID: 12697243 [PubMed - as supplied by publisher]

      __________________________________________________
      Do you Yahoo!?
      The New Yahoo! Search - Faster. Easier. Bingo
      http://search.yahoo.com
    Your message has been successfully submitted and would be delivered to recipients shortly.